Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Rectal cancer
Stage/Subtype:  stage III rectal cancer
Trial Type:  Treatment
Results 1-25 of 74 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CDR0000577892, NCI-2015-01484, NCI-2014-01372, SINGAPORE-07-32-LGI, SINGAPORE-ICR-02, ICR-02, SINGAPORE-ASCOLT, NCT00565708
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30182, NCI-2016-01102, 2016-000202-11, NCT02788279
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Cyclodextrin-Based Polymer-Camptothecin CRLX10, Capecitabine, and Radiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1315, NCI-2014-00897, NCT02010567
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym004-09, NCI-2016-00919, NCT02568046
Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20150195, NCI-2016-01042, NCT02713529
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMT212X2106, NCI-2016-01156, 2015-005019-34, NCT02703571
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Glutaminase Inhibitor CB-839 and Capecitabine in Treating Patients with Advanced Solid Tumors or Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: CASE1216, NCI-2016-01647, NCT02861300
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 0911010739, NCI-2010-01001, NCT01053013
Irinotecan Hydrochloride and Cetuximab with or without Ramucirumab in Treating Patients with Advanced Colorectal Cancer with Progressive Disease after Treatment with Bevacizumab-Containing Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7208, NCI-2011-02018, CDR0000666736, ECOG-E7208, NCT01079780
Combination Chemotherapy, Bevacizumab, and Cholecalciferol in Treating Patients with Previously Untreated Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-436, NCI-2012-00662, NCT01516216
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, CIR00009096, NA_00069666, NCI-2013-01567, NCT01639131
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-224, NCI-2014-01095, NCT01776307
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin before Surgery in Treating Patients with Stage II-III Rectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3R-12-2, NCI-2013-01069, 3C-12-2, HS-12-00726, ML28263, NCT01871571
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NCT01876511
Chemotherapy before or after Chemoradiation Followed by Surgery or Non-operative Management in Treating Patients with Previously Untreated Stage II-III Rectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-213, NCI-2013-02356, NCT02008656
Chemoradiation or Brachytherapy before Surgery in Treating Patients with Rectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1360, NCI-2014-00731, NA_00082167, NCI-2014-00125, NCT02017704
Start Over